Topics

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b

2019-11-14 17:39:51 | BioPortfolio

Summary

This is an open label, randomized, multi-center, comparative study. Subjects will be screened prior to study entry to establish eligibility. 100 Subjects who meet all the selection criteria will be randomly assigned 1:1:1:1:1 to (A) QL007 100 mg QD+ Tenofovir dipirofurate fumarate (TDF)300 mg QD, (B) QL007 200 mg QD+ TDF 300 mg QD, (C) QL007 400 mg QD+ TDF 300 mg QD, (D) QL007 200 mg BID+ TDF 300 mg QD, (E) TDF 300 mg QD.

The purpose of this study was to evaluate the efficacy and safety of QL-007 in combination with TDF in HBeAg positive patients with chronic hepatitis b, and to recommend a reasonable regimen for phase III study.

Description

The subjects received the drug treatment for a total of 96 weeks, which was divided into two stages: the first stage: 0-24 weeks as the core treatment period and 25-48 weeks as the extended treatment period. The second stage: 49-96 weeks is the extended treatment period,subjects will enter the second stage of treatment according to the dose of the first stage. When the efficacy data of the first phase determine the optimal dose of QL-007, all subjects entering the second phase will receive the optimal dose of QL-007 and continue treatment with tenofovir dipirofurate fumarate (QL-007 XX mg+TDF) for the second phase 49-96 weeks of extended treatment.

Study Design

Conditions

Chronic Hepatitis b

Intervention

TDF tablet, QL-007

Location

Southern Hospital of Southern Medical University
Guangzhou
Guangdong
China
510000

Status

Recruiting

Source

Qilu Pharmaceutical Co., Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-11-14T17:39:51-0500

Clinical Trials [2494 Associated Clinical Trials listed on BioPortfolio]

A Study Evaluating ABI-H0731 as Adjunctive Therapy in HBeAg-positive Patients With Chronic Hepatitis B

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care HBV medication is safe and effective in patients with chronic hepatitis B.

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response ...

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

This randomized controlled trial is designed to evaluate safety, effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different Nitazoxanide (NTZ) ...

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy

This is an open label, randomized, multi-center, comparative study. Subjects will be screened prior to study entry to establish eligibility. 60 Subjects who meet all the selection criteria...

A Study Evaluating ABI-H0731+ NUC vs NUC Alone for the Treatment of Viremic HBeAg-positive, CHB Patients

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care HBV medication is safe and effective in patients with chronic hepatitis B.

PubMed Articles [7403 Associated PubMed Articles listed on BioPortfolio]

Chronic Hepatitis E is associated with Cholangitis.

Sporadic hepatitis E is an emerging indigenous disease in Europe induced by genotype 3 of the virus. While the disease takes an acute self-limited course in immunocompetent individuals, under immunoco...

General immunological reactivity of patient's organism with chronic hepatitis С.

Introduction: Nowadays, the number of chronic carriers of hepatitis C virus (HCV) is considered to be from around 150 to 500 million by the most of infectionists and epidemiologists. Being one of the ...

Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.

Fibrosing cholestatic hepatitis (FCH) is an uncommon form of liver injury that often progresses to fulminant liver failure(1). FCH is well-described in immunosuppressed patients, particularly after tr...

Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B.

Seroclearance of hepatitis B surface antigen (HBsAg) is a potentially achievable target of chronic hepatitis B (CHB). Plasma proteins relevant to HBsAg seroclearance remain undetermined.

Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation: A report of two cases.

Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have demonstrated that immunocompromised patients such as those receiving solid-organ transplantati...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.

INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.

A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.

A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus.

More From BioPortfolio on "An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b"

Quick Search

Relevant Topics

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Trial